E-resources
Peer reviewed
Open access
-
Richardson, Paul G; Jacobus, Susanna J; Weller, Edie A; Hassoun, Hani; Lonial, Sagar; Raje, Noopur S; Medvedova, Eva; McCarthy, Philip L; Libby, Edward N; Voorhees, Peter M; Orlowski, Robert Z; Anderson, Jr, Larry D; Zonder, Jeffrey A; Milner, Carter P; Gasparetto, Cristina; Agha, Mounzer E; Khan, Abdullah M; Hurd, David D; Gowin, Krisstina; Kamble, Rammurti T; Jagannath, Sundar; Nathwani, Nitya; Alsina, Melissa; Cornell, R Frank; Hashmi, Hamza; Campagnaro, Erica L; Andreescu, Astrid C; Gentile, Teresa; Liedtke, Michaela; Godby, Kelly N; Cohen, Adam D; Openshaw, Thomas H; Pasquini, Marcelo C; Giralt, Sergio A; Kaufman, Jonathan L; Yee, Andrew J; Scott, Emma; Torka, Pallawi; Foley, Amy; Fulciniti, Mariateresa; Hebert, Kyle; Samur, Mehmet K; Masone, Kelly; Maglio, Michelle E; Zeytoonjian, Andrea A; Nadeem, Omar; Schlossman, Robert L; Laubach, Jacob P; Paba-Prada, Claudia; Ghobrial, Irene M; Perrot, Aurore; Moreau, Philippe; Avet-Loiseau, Hervé; Attal, Michel; Anderson, Kenneth C; Munshi, Nikhil C
New England journal of medicine/The New England journal of medicine, 07/2022, Volume: 387, Issue: 2Journal Article
In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone RVD), followed by lenalidomide maintenance therapy until disease progression, is unknown. In this phase 3 trial, adults (18 to 65 years of age) with symptomatic myeloma received one cycle of RVD. We randomly assigned these patients, in a 1:1 ratio, to receive two additional RVD cycles plus stem-cell mobilization, followed by either five additional RVD cycles (the RVD-alone group) or high-dose melphalan plus ASCT followed by two additional RVD cycles (the transplantation group). Both groups received lenalidomide until disease progression, unacceptable side effects, or both. The primary end point was progression-free survival. Among 357 patients in the RVD-alone group and 365 in the transplantation group, at a median follow-up of 76.0 months, 328 events of disease progression or death occurred; the risk was 53% higher in the RVD-alone group than in the transplantation group (hazard ratio, 1.53; 95% confidence interval CI, 1.23 to 1.91; P<0.001); median progression-free survival was 46.2 months and 67.5 months. The percentage of patients with a partial response or better was 95.0% in the RVD-alone group and 97.5% in the transplantation group (P = 0.55); 42.0% and 46.8%, respectively, had a complete response or better (P = 0.99). Treatment-related adverse events of grade 3 or higher occurred in 78.2% and 94.2%, respectively; 5-year survival was 79.2% and 80.7% (hazard ratio for death, 1.10; 95% CI, 0.73 to 1.65). Among adults with multiple myeloma, RVD plus ASCT was associated with longer progression-free survival than RVD alone. No overall survival benefit was observed. (Funded by the National Heart, Lung, and Blood Institute and others; DETERMINATION ClinicalTrials.gov number, NCT01208662.).
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.